Colorectal cancer (CRC) is one of the most commonly occurring human malignancies (Parkin, 2001) and in advanced CRC, the epidermal growth factor receptor (EGFR) and/or its ligands are frequently overexpressed and have been implicated in increased risk of metastasis and hence poor prognosis (reviewed by Spano et al, 2005) and additionally, increased EGFR expression has also been associated with chemo-refractory disease (Saltz et al, 2001). This evidence concerns the gene EGFR and colorectal carcinoma.